| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.
|
J Clin Oncol
|
2008
|
10.29
|
|
2
|
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
|
J Clin Oncol
|
2004
|
7.04
|
|
3
|
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
|
J Clin Oncol
|
2008
|
5.78
|
|
4
|
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
|
J Clin Oncol
|
2007
|
4.29
|
|
5
|
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
|
J Clin Oncol
|
2007
|
4.14
|
|
6
|
The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03.
|
J Clin Oncol
|
1993
|
4.09
|
|
7
|
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
|
J Clin Oncol
|
2005
|
3.88
|
|
8
|
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2004
|
3.10
|
|
9
|
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
|
Lancet Oncol
|
2010
|
2.73
|
|
10
|
Towards a pan-European consensus on the treatment of patients with colorectal liver metastases.
|
Eur J Cancer
|
2006
|
2.51
|
|
11
|
CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR.
|
Eur J Cancer
|
1999
|
2.24
|
|
12
|
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
|
Lancet Oncol
|
2012
|
1.98
|
|
13
|
Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group.
|
Br J Cancer
|
2000
|
1.93
|
|
14
|
A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.
|
J Clin Oncol
|
1987
|
1.75
|
|
15
|
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG).
|
Br J Cancer
|
2006
|
1.70
|
|
16
|
Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma.
|
Cancer
|
2004
|
1.44
|
|
17
|
Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.
|
Clin Colorectal Cancer
|
2006
|
1.34
|
|
18
|
Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?
|
Ann Surg Oncol
|
2006
|
1.30
|
|
19
|
Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer.
|
Br J Cancer
|
2008
|
1.25
|
|
20
|
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.
|
Br J Cancer
|
2003
|
1.25
|
|
21
|
Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2009
|
1.24
|
|
22
|
Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival.
|
Int J Colorectal Dis
|
2006
|
1.20
|
|
23
|
Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.
|
J Clin Oncol
|
1996
|
1.16
|
|
24
|
Stereotactic body radiation therapy for liver metastases.
|
Eur J Cancer
|
2009
|
1.13
|
|
25
|
Therapeutic strategy in unresectable metastatic colorectal cancer.
|
Ther Adv Med Oncol
|
2012
|
1.07
|
|
26
|
Management of liver metastases from colorectal cancer.
|
Oncology (Williston Park)
|
2006
|
1.05
|
|
27
|
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
|
Ann Oncol
|
2009
|
0.93
|
|
28
|
A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens.
|
Br J Cancer
|
2006
|
0.87
|
|
29
|
A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer.
|
Invest New Drugs
|
2008
|
0.82
|
|
30
|
Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy.
|
Med Oncol
|
2010
|
0.79
|